5 citations
,
April 2017 in “The journal of investigative dermatology/Journal of investigative dermatology”
This study reports on an ongoing Phase I/IIa clinical trial of ex vivo gene therapy for treating severe Recessive Dystrophic Epidermolysis Bullosa, involving six adult participants with COL7A1 mutations resulting in deficient type VII collagen production.
June 2025 in “Current Issues in Molecular Biology”
In this study, researchers using a UVB-induced mouse model identified the geneCOL7A1 as a novel marker for hair luster, finding that minoxidil, caffeine, and biotin effectively restored its expression, indicating potential therapeutic strategies.
June 2023 in “bioRxiv (Cold Spring Harbor Laboratory)”
This study developed new immortalized keratinocyte cell lines lacking COL7A1 using CRISPR/Cas9 technology, providing a valuable model to explore the biology and treatment options for recessive dystrophic epidermolysis bullosa.
The user tried Minoxidil, PRP, Hair Carboxytherapy, and topical Dutasteride with limited success and is now on oral Dutasteride. They are experiencing some hair loss reduction but no significant density improvement, leading to feelings of depression.